Research Papers:

HER3 over-expression and overall survival in gastrointestinal cancers

Yadong Wang _, Haiyan Yang and Guangcai Duan

PDF  |  HTML  |  How to cite

Oncotarget. 2015; 6:42868-42878. https://doi.org/10.18632/oncotarget.5998

Metrics: PDF 1189 views  |   HTML 1463 views  |   ?  


Yadong Wang1,2, Haiyan Yang3, Guangcai Duan2

1Department of Toxicology, Henan Center for Disease Control and Prevention, Zhengzhou 450016, China

2Henan Collaborative Innovation Center of Molecular Diagnosis and Laboratory Medicine, Xinxiang Medical University, Xinxiang 453003, China

3Department of Epidemiology, School of Public Health, Zhengzhou University, Zhengzhou 450001, China

Correspondence to:

Yadong Wang, e-mail: [email protected], e-mail: [email protected], e-mail: [email protected]

Keywords: HER3, gastrointestinal cancers, overall survival

Received: August 18, 2015     Accepted: October 05, 2015     Published: October 17, 2015


Published studies on the association between human epidermal factor receptor 3 (HER3) expression and overall survival (OS) in gastrointestinal cancers have yielded conflicting results. The aim of this study was to explore the association of HER3 over-expression with OS in gastrointestinal cancers. A systematic search was performed through Medline/PubMed, Embase, Science Direct and Elsevier. The summary odds ratio (OR) with 95% confidence interval (CI) was calculated to estimate the strength of the association. Overall, we observed that HER3 over-expression was associated with worse OS at five years (OR = 1.38, 95% CI: 1.04–1.82); however, HER3 over-expression was not associated with worse OS at three years (OR = 1.33, 95% CI: 0.97–1.84). The cumulative meta-analysis showed similar results. In subgroup analyses by tumor type, HER3 over-expression in gastric cancers was associated with worse OS at both three years (OR = 1.69, 95% CI: 1.28–2.25) and five years (OR = 1.74, 95% CI: 1.26–2.41). In conclusion, our results suggest that HER3 over-expression may be associated with worse overall survival in gastric cancers. Well-designed studies with a large sample size are required to further confirm our findings.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 5998